Lates News

Each day's AI news, Guojin Securities released a research report on April 2, giving Weigao Blood Net (603014.SH) a "buy" rating. The rating reasons mainly include: 1) stable and strong growth in performance, short-term pressure on profitability, excellent operating quality; 2) dual drive at home and abroad, strategic layout opening up new growth space. (Daily Economic News)